Cargando…

Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization

Broadly neutralizing antibodies to HIV-1 usually develops in chronic infections. Here, we examined the basis of enhanced sensitivity of an env clone amplified from cross neutralizing plasma of an antiretroviral naïve chronically infected Indian patient (ID50 >600-fold higher compared to other aut...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringe, Rajesh, Das, Lipsa, Choudhary, Ipsita, Sharma, Deepak, Paranjape, Ramesh, Chauhan, Virander Singh, Bhattacharya, Jayanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463516/
https://www.ncbi.nlm.nih.gov/pubmed/23056416
http://dx.doi.org/10.1371/journal.pone.0046713
_version_ 1782245296814686208
author Ringe, Rajesh
Das, Lipsa
Choudhary, Ipsita
Sharma, Deepak
Paranjape, Ramesh
Chauhan, Virander Singh
Bhattacharya, Jayanta
author_facet Ringe, Rajesh
Das, Lipsa
Choudhary, Ipsita
Sharma, Deepak
Paranjape, Ramesh
Chauhan, Virander Singh
Bhattacharya, Jayanta
author_sort Ringe, Rajesh
collection PubMed
description Broadly neutralizing antibodies to HIV-1 usually develops in chronic infections. Here, we examined the basis of enhanced sensitivity of an env clone amplified from cross neutralizing plasma of an antiretroviral naïve chronically infected Indian patient (ID50 >600-fold higher compared to other autologous env clones). The enhanced autologous neutralization of pseudotyped viruses expressing the sensitive envelope (Env) was associated with increased sensitivity to reagents and monoclonal antibodies targeting distinct sites in Env. Chimeric viruses constructed by swapping fragments of sensitive Env into resistant Env backbone revealed that the presence of unique residues within C2V3 region of gp120 governed increased neutralization. The enhanced virus neutralization was also associated with low CD4 dependence as well as increased binding of Env trimers to IgG1b12 and CD4-IgG2 and was independent of gp120 shedding. Our data highlighted vulnerabilities in the Env obtained from cross neutralizing plasma associated with the exposure of discontinuous neutralizing epitopes and enhanced autologous neutralization. Such information may aid in Env-based vaccine immunogen design.
format Online
Article
Text
id pubmed-3463516
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34635162012-10-09 Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization Ringe, Rajesh Das, Lipsa Choudhary, Ipsita Sharma, Deepak Paranjape, Ramesh Chauhan, Virander Singh Bhattacharya, Jayanta PLoS One Research Article Broadly neutralizing antibodies to HIV-1 usually develops in chronic infections. Here, we examined the basis of enhanced sensitivity of an env clone amplified from cross neutralizing plasma of an antiretroviral naïve chronically infected Indian patient (ID50 >600-fold higher compared to other autologous env clones). The enhanced autologous neutralization of pseudotyped viruses expressing the sensitive envelope (Env) was associated with increased sensitivity to reagents and monoclonal antibodies targeting distinct sites in Env. Chimeric viruses constructed by swapping fragments of sensitive Env into resistant Env backbone revealed that the presence of unique residues within C2V3 region of gp120 governed increased neutralization. The enhanced virus neutralization was also associated with low CD4 dependence as well as increased binding of Env trimers to IgG1b12 and CD4-IgG2 and was independent of gp120 shedding. Our data highlighted vulnerabilities in the Env obtained from cross neutralizing plasma associated with the exposure of discontinuous neutralizing epitopes and enhanced autologous neutralization. Such information may aid in Env-based vaccine immunogen design. Public Library of Science 2012-10-03 /pmc/articles/PMC3463516/ /pubmed/23056416 http://dx.doi.org/10.1371/journal.pone.0046713 Text en © 2012 Ringe et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Ringe, Rajesh
Das, Lipsa
Choudhary, Ipsita
Sharma, Deepak
Paranjape, Ramesh
Chauhan, Virander Singh
Bhattacharya, Jayanta
Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title_full Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title_fullStr Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title_full_unstemmed Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title_short Unique C2V3 Sequence in HIV-1 Envelope Obtained from Broadly Neutralizing Plasma of a Slow Progressing Patient Conferred Enhanced Virus Neutralization
title_sort unique c2v3 sequence in hiv-1 envelope obtained from broadly neutralizing plasma of a slow progressing patient conferred enhanced virus neutralization
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463516/
https://www.ncbi.nlm.nih.gov/pubmed/23056416
http://dx.doi.org/10.1371/journal.pone.0046713
work_keys_str_mv AT ringerajesh uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT daslipsa uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT choudharyipsita uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT sharmadeepak uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT paranjaperamesh uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT chauhanvirandersingh uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization
AT bhattacharyajayanta uniquec2v3sequenceinhiv1envelopeobtainedfrombroadlyneutralizingplasmaofaslowprogressingpatientconferredenhancedvirusneutralization